United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

gulf drug llc dubai-street no 10 - efmoroctocog alfa - injection - 2000 iu/vial - n/a-n/a

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

efmoroctocog alfa ( recombinant coagulation factor viii ) -

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

swedish orphan biovitrum international ab, sweden - efmoroctocog alfa - powder and solvent for solution for injection - 3000 iu

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

swedish orphan biovitrum international ab, sweden - efmoroctocog alfa - powder and solvent for solution for injection - 250 iu

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

swedish orphan biovitrum international ab, sweden - efmoroctocog alfa - powder and solvent for solution for injection - 2000 iu

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

swedish orphan biovitrum international ab, sweden - efmoroctocog alfa - powder and solvent for solution for injection - 1500 iu

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

swedish orphan biovitrum international ab, sweden - efmoroctocog alfa - powder and solvent for solution for injection - 1000 iu

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

swedish orphan biovitrum international ab, sweden - efmoroctocog alfa - powder and solvent for solution for injection - 500 iu

United States - English - NLM (National Library of Medicine)

bioverativ therapeutics inc. - efmoroctocog alfa (unii: 7pcm518ylr) (efmoroctocog alfa - unii:7pcm518ylr) - (1-743)-(1638-2332)-blood-coagulation factor viii (synthetic human) fusion protein with immunoglobulin g1 (synthetic human fc domain fragment), (1444-6'),(1447-9')-bis(disulfide) with immunoglobulin g1 (synthetic human fc domain fragment) 250 [iu] in 3 ml - eloctate, antihemophilic factor (recombinant), fc fusion protein, is a recombinant dna derived, antihemophilic factor indicated in adults and children with hemophilia a (congenital factor viii deficiency) for: - on-demand treatment and control of bleeding episodes, - perioperative management of bleeding, - routine prophylaxis to reduce the frequency of bleeding episodes. limitation of use eloctate is not indicated for the treatment of von willebrand disease. eloctate is contraindicated in patients who have had life-threatening hypersensitivity reactions to eloctate or its excipients (sucrose, sodium chloride, l-histidine, calcium chloride and polysorbate 20). risk summary there are no studies of eloctate use in pregnant women to inform a drug-associated risk. the background risk of major birth defects and miscarriage in the indicated population is unknown; however, the background risk of major birth defects in the u.s. general population is 2-4% and of miscarriage is 15-20% of clinically recognized pregnanci